Eliciting an Immunostimulatory Tumor Microenvironment to Enhance the Antitumor Efficacy by Targeted Cancer Immunotherapy. Issue 9 (11th July 2022)

• Record Type: Journal Article
• Authors: Zhang, Ya‐Xuan; Zhang, Jun‐Jie; Wang, Wei; Guo, Xiao‐Ying; Hou, Li‐Shuang; Zhang, Tang‐Rui; Wang, Bao‐Long; Kou, Fang; Huan, Meng‐Lei; He, Wei; Zhou, Si‐Yuan; Zhang, Bang‐Le
• Is Part Of: Advanced therapeutics. Volume 5:Issue 9(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-07-11
• Subjects: macrophage polarization -- melanoma -- targeted cancer immunotherapy -- tumor microenvironment; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.202200070
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Tumor‐associated macrophages (TAMs) in tumor microenvironment represent an ideal therapeutic target for cancer immunotherapy. A targeted cancer immunotherapy strategy through reprogramming M2 macrophages to reverse the immunosuppressive microenvironment is proposed and the antitumor effects via targeted immunostimulatory therapy are evaluated. The developed M2‐macrophage‐targeted nanoparticles (M2‐TNPs) can specially target and reprogram the M2 macrophages via polarization to the antitumor M1 phenotype. Compared with nontargeted nanoparticles, M2‐TNPs loading zoledronic acid can specifically be recognized by M2 macrophages but not other macrophages and mounted productive antitumor responses, showing enhanced antitumor efficacy by targeted immunostimulation in vitro and in vivo. Moreover, when combining the chemotherapeutic drug dacarbazine with M2‐TNPs for treatment of melanoma, a dramatic synergistic effect in cancer therapy through eliciting an immunostimulatory tumor microenvironment to restore the antitumor immunity is demonstrated. These studies provide preclinical evidence that targeted TAM‐reprogramming treatment strategies can hold tremendous promise in cancer immunotherapy. Abstract : A targeted cancer immunotherapy strategy through reprogramming M2 macrophages to reverse the immunosuppressive tumor microenvironment is proposed. The developed therapy system M2‐macrophage‐targeted nanoparticles can specially deliver therapeutic drug to the protumor M2 macrophages for enhancing the performance of immunostimulatory cancer immunotherapy, showing enhanced antitumor effects by targeted cancer immunotherapy in vitro and in vivo.